Journal
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 11, Issue -, Pages 316-329Publisher
WILEY
DOI: 10.1111/jth.12219
Keywords
cangrelor; clopidogrel; prasugrel; thrombosis; ticagrelor
Categories
Funding
- Bristol Myers Squibb
- Sanofi-Aventis
- Eli Lilly Co
- Daiichi Sankyo, Inc.
- Medicines Company
- Portola
- Novartis
- Accumetrics
- AstraZeneca
- Merck
- Evolva
- Abbott Vascular
- GlaxoSmithKline
- Otsuka
- Eisai
Ask authors/readers for more resources
Recurrent atherothrombotic events in patients with acute coronary syndromes (ACS) and/or those undergoing percutaneous coronary intervention (PCI) are essentially platelet-driven processes, underscoring the need for effective pharmacological platelet inhibition. Dual antiplatelet therapy with aspirin and clopidogrel has been, for over a decade, the mainstay of antiplatelet management in ACS/PCI. However, atherothrombotic events continue to occur in a relevant proportion of subjects despite the benefit of this combination, which has led to the clinical development of newer and more potent antiplatelet drugs. Two of these, prasugrel and ticagrelor, have been recently approved for clinical use. The scope of this manuscript is to provide an up-to-date overview on new antiplatelet drugs in the setting of ACS and PCI, including the most recent advances on newly approved agents as well as on emerging compounds in clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available